BIOLIFE4D
Develops 3D bioprinting technology to create patient-specific human hearts for transplantation, using the patient's own cells to eliminate organ rejection and reduce transplant waiting lists.
- CEO / Founder
- Steven Morris
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $13.3M
- Latest Round
- Crowdfunding
- Key Investors
- Johnson & Johnson Innovation - JLABS
Technology & Products
Key Products
Mini-heart for cardiotoxicity testing; Cardiac patches for tissue repair; Full human heart for transplantation (in development)
Technological Advantage
Proprietary bioprinting process optimized for cardiac tissue, leveraging adult and iPS stem cells; strategic partnerships with Argonne National Laboratory for advanced research; technology focuses on optimization rather than invention, accelerating development.
Differentiation
Value Proposition
Enables on-demand, personalized heart transplants with zero rejection risk, potentially saving lives by addressing the 114,000+ U.S. organ transplant waiting list and reducing dependency on donors.
How They Differentiate
Focuses exclusively on 3D bioprinting human hearts for transplantation, unlike competitors targeting broader tissue engineering or organ-on-chip models; uses patient-specific cells for zero rejection, while others may use generic cell lines.
Market & Competition
Target Customers
Patients with heart disease requiring transplants, pharmaceutical companies for drug testing
Industry Verticals
Medical; Pharmaceutical
Competitors
3D Bioprinting Solutions; Aspect Biosystems; regenHU
Growth & Milestones
Growth Metrics
Annual revenue reached $750K as of January 2024; 7 employees across North America; raised $13.3M in funding
Major Milestones
Successfully 3D bioprinted human cardiac tissue (June 2018); Became first U.S. company to bioprint a mini-heart for cardiotoxicity testing (September 2019); Filed for $17.5M IPO with SEC